The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Somasundaram, R.
Right arrow Articles by Herlyn, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Somasundaram, R.
Right arrow Articles by Herlyn, D.

The Journal of Immunology, Vol 155, Issue 6 3253-3261, Copyright © 1995 by American Association of Immunologists

ARTICLES

Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody

R Somasundaram, J Zaloudik, L Jacob, A Benden, M Sperlagh, E Hart, G Marks, M Kane, M Mastrangelo and D Herlyn
Wistar Institute, Philadelphia, PA 19104, USA.

Polyclonal goat anti-idiotypic Abs directed against anti-human gastrointestinal carcinoma mAb GA733 were administered to 13 colon cancer patients who had their primary tumor and lymph node metastases removed before immunotherapy. Patients received four s.c. doses (0.5 to 8 mg each) of alum-precipitated anti-idiotypic Ab. Seven of the 13 patients produced anti-anti-Ids that bound specifically to the GA733 epitope on tumor cells and shared idiotopes with mAb GA733. In four of the seven responding patients, anti-Id therapy specifically modulated T cell responses. In two patients who did not demonstrate GA733 Ag/anti- Id-reactive T cells before therapy, anti-Id administration induced CD4+, MHC class II-dependent T cells that specifically proliferated in culture in response to stimulation with either anti-Id or GA733 Ag. In two other patients who did demonstrate Ag/anti-Id-reactive T cells before therapy, anti-Id administration transiently induced lymphocytes that suppressed the proliferative responses of cultured pretherapy lymphocytes to stimulation with anti-Id or GA733 Ag. Nine of the 13 treated patients showed no evidence of disease after 39 to 86 mo of observation. Five of these patients developed Ag-specific Ab3 and one had, in addition, a T cell response.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. M. Hernandez, D. Toledo, D. Martinez, T. Grinan, V. Brito, A. Macias, S. Alfonso, T. Rondon, E. Suarez, A. M. Vazquez, et al.
Characterization of the Antibody Response against NeuGcGM3 Ganglioside Elicited in Non-Small Cell Lung Cancer Patients Immunized with an Anti-Idiotype Antibody
J. Immunol., November 1, 2008; 181(9): 6625 - 6634.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. K. Swoboda, R. Somasundaram, L. Caputo, E. M. Ochoa, P. A. Gimotty, F. M. Marincola, P. Van Belle, S. Barth, D. Elder, D. Guerry, et al.
Shared MHC Class II-Dependent Melanoma Ribosomal Protein L8 Identified by Phage Display
Cancer Res., April 15, 2007; 67(8): 3555 - 3559.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Sabbatini, J. Dupont, C. Aghajanian, F. Derosa, E. Poynor, S. Anderson, M. Hensley, P. Livingston, A. Iasonos, D. Spriggs, et al.
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clin. Cancer Res., September 15, 2006; 12(18): 5503 - 5510.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Somasundaram, R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, et al.
Human Leukocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients.
Cancer Res., March 15, 2006; 66(6): 3287 - 3293.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Schmetzer, G. Moldenhauer, R. Riesenberg, J. R. Pires, P. Schlag, and A. Pezzutto
Quality of Recombinant Protein Determines the Amount of Autoreactivity Detected against the Tumor-Associated Epithelial Cell Adhesion Molecule Antigen: Low Frequency of Antibodies against the Natural Protein
J. Immunol., January 15, 2005; 174(2): 942 - 952.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al.
Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R)
J. Immunol., November 15, 2004; 173(10): 6472 - 6480.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mosolits, K. Markovic, J.-E. Frodin, L. Virving, C. G. M. Magnusson, M. Steinitz, J. Fagerberg, and H. Mellstedt
Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma Patients
Clin. Cancer Res., August 15, 2004; 10(16): 5391 - 5402.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. L. Murray, M. Gillogly, K. Kawano, C. L. Efferson, J. E. Lee, M. Ross, X. Wang, S. Ferrone, and C. G. Ioannides
Fine Specificity of High Molecular Weight-Melanoma-Associated Antigen-Specific Cytotoxic T Lymphocytes Elicited by Anti-Idiotypic Monoclonal Antibodies in Patients with Melanoma
Cancer Res., August 1, 2004; 64(15): 5481 - 5488.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Lomas, W. Liauw, D. Packham, K. Williams, A. Kelleher, J. Zaunders, and R. Ward
Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy
Ann. Onc., February 1, 2004; 15(2): 324 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Ullenhag, J.-E. Frodin, S. Mosolits, S. Kiaii, M. Hassan, M. C. Bonnet, P. Moingeon, H. Mellstedt, and H. Rabbani
Immunization of Colorectal Carcinoma Patients with a Recombinant Canarypox Virus Expressing the Tumor Antigen Ep-CAM/KSA (ALVAC-KSA) and Granulocyte Macrophage Colony- stimulating Factor Induced a Tumor-specific Cellular Immune Response
Clin. Cancer Res., July 1, 2003; 9(7): 2447 - 2456.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Somasundaram, L. Jacob, R. Swoboda, L. Caputo, H. Song, S. Basak, D. Monos, D. Peritt, F. Marincola, D. Cai, et al.
Inhibition of Cytolytic T Lymphocyte Proliferation by Autologous CD4+/CD25+ Regulatory T Cells in a Colorectal Carcinoma Patient Is Mediated by Transforming Growth Factor-{beta}
Cancer Res., September 15, 2002; 62(18): 5267 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Gruber, L. J. M. van Haarlem, S. O. Warnaar, E. Holz, and G. Riethmüller
The Human Antimouse Immunoglobulin Response and the Anti-idiotypic Network Have No Influence on Clinical Outcome in Patients with Minimal Residual Colorectal Cancer Treated with Monoclonal Antibody CO17-1A
Cancer Res., April 1, 2000; 60(7): 1921 - 1926.
[Abstract] [Full Text]

Home page
 Neuro OncolHome page
J. H. Sampson
THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.
Neuro-oncol, January 1, 1999; 1(1): 33 - 42.
[PDF]

Home page
 J. Biol. Chem.Home page
M. Trebak, G. E. Begg, J. M. Chong, E. V. Kanazireva, D. Herlyn, and D. W. Speicher
Oligomeric State of the Colon Carcinoma-associated Glycoprotein GA733-2 (Ep-CAM/EGP40) and Its Role in GA733-mediated Homotypic Cell-Cell Adhesion
J. Biol. Chem., January 12, 2001; 276(3): 2299 - 2309.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1995 by The American Association of Immunologists, Inc. All rights reserved.